Premium
Comparison the clinical outcomes with altered versus conventional fractionated radiotherapy plus concurrent chemotherapy for advanced nasopharyngeal carcinoma
Author(s) -
Lin PoJu,
Twu ChihWen,
Liu YiChun,
Lin TianYun,
Wang WenYi,
Lin JinChing
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25084
Subject(s) - nasopharyngeal carcinoma , medicine , radiation therapy , urology , oncology , chemoradiotherapy , progression free survival , chemotherapy , overall survival , nuclear medicine
Background The purpose of this study was to compare the long‐term survivals between altered fractionated and conventional fractionated radiotherapy with the same concurrent chemoradiotherapy (concurrent CRT) for patients with advanced nasopharyngeal carcinoma (NPC). Methods We retrospectively reviewed 203 patients with NPC who received radiotherapy (RT) by either a conventional fractionated (70‐74 Gy/35‐37 fractions/7‐8 weeks) or altered fractionated (72‐75 Gy/45 fractions/6 weeks) schedule plus the same concurrent CRT. Results The patient characteristics between conventional fractionated and altered fractionated groups showed similar distribution. The 5‐year rates of nasopharyngeal failure‐free, neck failure‐free, and distant metastasis failure‐free survival between conventional fractionated and altered fractionated groups were 88% versus 86% ( P = .7781), 95% versus 93% ( P = .4176), and 76% versus 73% ( P = .4029), respectively. The overall survival (OS; 5‐year rates were 64% versus 62%; P = .4812) and progression‐free survival (PFS; 5‐year rates were 67% versus 63%; P = .3829) rates also showed no significant differences. The acute and late toxicities were similar between both groups. Conclusion Altered fractionated and conventional fractionated RT achieved similar survival outcome when concurrent CRT strategy was used for advanced NPC.